Tivantinib
Type 1 Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Type 1 Papillary Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Crizotinib National Cancer Institute (NCI) | Phase 2 | B |
su011248 National Cancer Institute (NCI) | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 2 | B |
Tas-102 National Cancer Institute (NCI) | Phase 2 | B |
View all 15 →
Same molecule, other indications
Tivantinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →